Video

Dr. Kahl Discusses Unmet Needs in MCL

Author(s):

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma (MCL).

Kahl says that the biggest unmet need in MCL is the lack of curative options, particularly with the rate of relapse being so high. This begins with improving outcomes in the frontline setting, and there are multiple novel targeted agents that are showing good activity in MCL, such as ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta). There is also interest in combination therapy with these novel agents and current standard therapies.

Ibrutinib is currently approved for relapsed disease, and is used frequently to treat these patients. It is being tested now in the frontline setting in the SHINE trial. The SHINE trial is a phase III trial of ibrutinib in combination with bendamustine and rituximab (Rituxan) in older patients with newly diagnosed MCL. The study aims to evaluate the safety and efficacy of the combination.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center